Chronic stable angina positron emission tomography (PET): Difference between revisions
(New page: {{Chronic stable angina}} '''Editors-In-Chief:''' C. Michael Gibson, M.S., M.D. [mailto:mgibson@perfuse.org] Phone:617-632-7753; {{CZ}}; '''Associate Editor-in-Chief:''' Smita Kohli, M...) |
No edit summary |
||
| Line 2: | Line 2: | ||
'''Editors-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; {{CZ}}; '''Associate Editor-in-Chief:''' Smita Kohli, M.D. | '''Editors-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; {{CZ}}; '''Associate Editor-in-Chief:''' Smita Kohli, M.D. | ||
== | ==Overview== | ||
[[Positron emission tomography]] is of particular value in the assessment of regional coronary blood flow reserve, myocardial perfusion, and the presence and extent of [[hibernating myocardium]]. | |||
==PET Modalities== | |||
*'''Rubidium-82''' or [[ammonia]] ('''N13''') can be used for assessment of myocardial perfusion. | |||
*Labeled carbohydrates such as '''fludeoxyglucose F-18''', lipids, and some amino acids can be used to asses myocardial metabolism and viable ischemic myocardium. | |||
==Sensitivity and Specificity== | |||
With combined assessment of myocardial perfusion and metabolism, the sensitivity and specificity for the detection of [[CAD]] may approach 95%. | |||
==Indications== | |||
PET is of value principally in '''difficult situations''' where in myocardial perfusion by [[Chronic stable angina myocardial perfusion scintigraphy|thallium scintigraphy]] and assessment of left ventricular systolic function by [[Chronic stable angina echocardiography|echocardiography]] do not reveal the extent of [[hibernating myocardium]]. | |||
==Disadvantages== | |||
Positron emission tomography is a very expensive noninvasive test and not readily available in every cardiology center. | |||
[[Category:Disease state]] | [[Category:Disease state]] | ||
Revision as of 01:20, 18 August 2011
|
Chronic stable angina Microchapters | ||
|
Classification | ||
|---|---|---|
| ||
| ||
|
Differentiating Chronic Stable Angina from Acute Coronary Syndromes | ||
|
Diagnosis | ||
|
Alternative Therapies for Refractory Angina | ||
|
Discharge Care | ||
|
Guidelines for Asymptomatic Patients | ||
|
Case Studies | ||
|
Chronic stable angina positron emission tomography (PET) On the Web | ||
|
FDA on Chronic stable angina positron emission tomography (PET) | ||
|
CDC onChronic stable angina positron emission tomography (PET) | ||
|
Chronic stable angina positron emission tomography (PET) in the news | ||
|
Blogs on Chronic stable angina positron emission tomography (PET) | ||
|
to Hospitals Treating Chronic stable angina positron emission tomography (PET) | ||
|
Risk calculators and risk factors for Chronic stable angina positron emission tomography (PET) | ||
Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Cafer Zorkun, M.D., Ph.D. [2]; Associate Editor-in-Chief: Smita Kohli, M.D.
Overview
Positron emission tomography is of particular value in the assessment of regional coronary blood flow reserve, myocardial perfusion, and the presence and extent of hibernating myocardium.
PET Modalities
- Rubidium-82 or ammonia (N13) can be used for assessment of myocardial perfusion.
- Labeled carbohydrates such as fludeoxyglucose F-18, lipids, and some amino acids can be used to asses myocardial metabolism and viable ischemic myocardium.
Sensitivity and Specificity
With combined assessment of myocardial perfusion and metabolism, the sensitivity and specificity for the detection of CAD may approach 95%.
Indications
PET is of value principally in difficult situations where in myocardial perfusion by thallium scintigraphy and assessment of left ventricular systolic function by echocardiography do not reveal the extent of hibernating myocardium.
Disadvantages
Positron emission tomography is a very expensive noninvasive test and not readily available in every cardiology center.